COMMUNIQUÉS West-GlobeNewswire

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
23/10/2026
EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients with advanced [...]
Enterome Phase 1/2 data show OncoMimics™ EO4010-induced CD8 T-cell expansion was associated with longer survival in patients with colorectal cancer
23/10/2026
Faster and higher expansion of tumor-targeting CD8 T cells associated with longer overall survival in previously treated mismatch repair proficient (pMMR) metastatic colorectal cancer EO4010 was well tolerated and [...]
KFSH Cuts the Wait for an Echocardiography Appointment from 126 Days to One
23/10/2026
RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has reduced the wait for the first available echocardiography appointment at its Heart Center of [...]
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
23/10/2026
Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor [...]
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
23/10/2026
In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed [...]
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
23/10/2026
FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea
23/10/2026
Pratteln, Switzerland, October 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes that its licensing partner Nxera Pharma Co., Ltd. (“Nxera”) has submitted a Marketing Authorization Application (MAA) to South [...]
IBA signe un contrat majeur pour une solution de stérilisation Be Efficient à haut débit en Allemagne
23/10/2026
Louvain-la-Neuve, Belgique, le 23 octobre 2026, 7h00 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et des solutions de faisceaux d’électrons et à rayons X [...]
IBA signs major contract for a high-throughput Be Efficient sterilization solution in Germany
23/10/2026
Louvain-la-Neuve, Belgium, October 23, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, announced [...]
Orange Hospice Receives BusinessRate Best of 2026 Award as a Hospice in Orange County
23/10/2026
Buena Park recognition reflects more than 40 five-star family reviews as the provider marks five years of hospice care in Orange County. Buena Park, CA, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orange Hospice has received [...]
Fangzhou Showcases Award-Winning AI Chronic Care Solution at Fortune China 500 Forum
23/10/2026
CHENGDU, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, was invited to showcase its “AI + Chronic [...]
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
22/10/2026
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern [...]
Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
22/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third quarter ended September [...]
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
22/10/2026
WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
22/10/2026
BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026 [...]
Ligand to Host Investor Day on December 8, 2026
22/10/2026
JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m [...]
Health Catalyst to Announce Third Quarter 2026 Operating Results and Host Conference Call on Thursday, November 5, 2026
22/10/2026
SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, will release [...]
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
22/10/2026
Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001) 89% and 81% reductions in risk of confirmed ≥30% and ≥40% eGFR declines, respectively [...]
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
22/10/2026
Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October [...]

Pages